BR112017023038A2 - imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa - Google Patents

imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa

Info

Publication number
BR112017023038A2
BR112017023038A2 BR112017023038A BR112017023038A BR112017023038A2 BR 112017023038 A2 BR112017023038 A2 BR 112017023038A2 BR 112017023038 A BR112017023038 A BR 112017023038A BR 112017023038 A BR112017023038 A BR 112017023038A BR 112017023038 A2 BR112017023038 A2 BR 112017023038A2
Authority
BR
Brazil
Prior art keywords
imidazopyrazines
pyrazolopyrimidines
receptor modulators
ampa receptor
compounds
Prior art date
Application number
BR112017023038A
Other languages
English (en)
Inventor
M Savall Bradley
M Swanson Devin
Wu Dongpei
K Ameriks Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112017023038A2 publication Critical patent/BR112017023038A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Abstract

a presente invenção refere-se a compostos da fórmula (i), e sais, n-óxidos ou solvatos farmaceuticamente aceitáveis dos mesmos, são também fornecidos, na presente invenção, composições farmacêuticas, compreendendo os compostos da fórmula (i), e métodos de uso de compostos da fórmula (i).
BR112017023038A 2015-04-29 2016-04-28 imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa BR112017023038A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154310P 2015-04-29 2015-04-29
PCT/US2016/029791 WO2016176457A1 (en) 2015-04-29 2016-04-28 Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
BR112017023038A2 true BR112017023038A2 (pt) 2018-07-03

Family

ID=55919907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023038A BR112017023038A2 (pt) 2015-04-29 2016-04-28 imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa

Country Status (12)

Country Link
US (1) US10513523B2 (pt)
EP (1) EP3288945B1 (pt)
JP (1) JP6800885B2 (pt)
KR (1) KR20170141768A (pt)
CN (1) CN107567452B (pt)
AU (1) AU2016255431B2 (pt)
BR (1) BR112017023038A2 (pt)
CA (1) CA2984307A1 (pt)
ES (1) ES2759348T3 (pt)
MX (1) MX2017013874A (pt)
NZ (1) NZ736055A (pt)
WO (1) WO2016176457A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037731B1 (ru) * 2016-10-26 2021-05-14 Янссен Фармацевтика Нв Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
CN107056789B (zh) * 2017-04-21 2019-03-29 陈剑 具有取代吡嗪并咪唑类衍生物,其制备及其在医药上的应用
JP7250687B2 (ja) * 2017-10-06 2023-04-03 武田薬品工業株式会社 複素環化合物
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
CA3120791A1 (en) * 2018-11-30 2020-06-04 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
TW202115054A (zh) * 2019-06-14 2021-04-16 比利時商健生藥品公司 經取代的雜芳族吡唑并－吡啶及其作為ｇｌｕｎ２ｂ受體調節劑的用途
CN114829362A (zh) * 2019-12-10 2022-07-29 成都倍特药业股份有限公司 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
WO2021219135A1 (zh) * 2020-04-30 2021-11-04 上海森辉医药有限公司 一种肌醇衍生物及其用途
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
TW251284B (pt) 1992-11-02 1995-07-11 Pfizer
US5688809A (en) 1994-02-10 1997-11-18 Pfizer Inc. 5-heteroarylindole derivatives
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
WO2002014294A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
AU2005279156B2 (en) 2004-09-03 2011-06-02 Merck Serono Sa Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
JP2010508328A (ja) * 2006-11-03 2010-03-18 グラクソ グループ リミテッド Ａｍｐａ受容体を強化する化合物および医薬におけるその使用
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
CN101939315A (zh) * 2007-12-06 2011-01-05 先灵公司 γ分泌酶调节剂
US20110312938A1 (en) 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
GB0822425D0 (en) * 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) * 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
ES2793723T3 (es) * 2010-08-10 2020-11-16 Takeda Pharmaceuticals Co Compuesto heterocíclico y uso del mismo como modulador alostérico positivo del receptor ampa
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
MY194104A (en) * 2015-04-29 2022-11-11 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators

Also Published As

Publication number Publication date
EP3288945A1 (en) 2018-03-07
CA2984307A1 (en) 2016-11-03
EP3288945B1 (en) 2019-09-18
AU2016255431B2 (en) 2020-05-07
CN107567452B (zh) 2020-07-07
JP2018514537A (ja) 2018-06-07
US20180118751A1 (en) 2018-05-03
CN107567452A (zh) 2018-01-09
US10513523B2 (en) 2019-12-24
MX2017013874A (es) 2018-06-22
AU2016255431A1 (en) 2017-10-26
WO2016176457A1 (en) 2016-11-03
JP6800885B2 (ja) 2020-12-16
NZ736055A (en) 2023-05-26
ES2759348T3 (es) 2020-05-08
KR20170141768A (ko) 2017-12-26

Similar Documents

Publication Publication Date Title
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
BR112018001650A2 (pt) compostos de heteroarila ou arila fundidos bicíclicos como moduladores de irak4
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
BR112016016844A2 (pt) Compostos heterocíclicos
BR112019005464A2 (pt) antagonistas de trpv4
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112017023080A2 (pt) compostos benzimidazolona e benzotiazolona e uso dos mesmos como moduladores do receptor de ampa
BR112019005416A2 (pt) antagonistas de trpv4
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112017004742A2 (pt) 2-azabiciclos substituídos e seus usos como moduladores de receptor de orexina
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016022046A8 (pt) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
BR112015012716A2 (pt) derivados de feniletilpiridina como inibidores de pde4
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
BR112017026191A2 (pt) compostos tricíclicos e seu uso como inibidores de fosfodiesterase
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]